Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?

Current Atherosclerosis Reports
Paola Toledo-Ibelles, Jaime Mas-Oliva

Abstract

The purpose of this review is to focus on the outcome of recent antioxidant interventions using synthetic and naturally occurring molecules established as adjuvant strategies to lipid-lowering or anti-inflammatory therapies designed to reduce the risk of cardiovascular disease. To date, accumulated evidence regarding oxidation as a pro-atherogenic factor indicates that redox biochemical events involved in atherogenesis are indeed a very attractive target for the management of cardiovascular disease in the clinic. Nevertheless, although evidence indicates that redox reactions are important in the initiation and progression of atherosclerosis, oxidation with a pro-atherogenic context does not eliminate the fact that oxidation participates in many cases as an essential messenger of important cellular signaling pathways. Therefore, disease management and therapeutic goals require not only high-precision and high-sensitivity methods to detect in plasma very low amounts of reducing and oxidizing molecules but also a much better understanding of the normal processes and metabolic pathways influenced and/or controlled by oxidative stress. As several methodologies have been specifically described for the quantification of the total anti...Continue Reading

References

Jan 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J L GoldsteinM S Brown
Dec 1, 1991·The Journal of Clinical Investigation·J L Witztum, D Steinberg
Jan 1, 1990·Free Radical Biology & Medicine·U P SteinbrecherM Lougheed
Nov 1, 1989·Archives of Biochemistry and Biophysics·P Di MascioH Sies
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T KitaC Kawai
Oct 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·C SuarnaR Stocker
Jul 18, 1997·Biochemical and Biophysical Research Communications·E Nishio, Y Watanabe
Aug 26, 1998·Proceedings of the National Academy of Sciences of the United States of America·O CynshiT Kodama
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsP Sleight
Jan 3, 2001·Nature Medicine·K J MooreM W Freeman
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Michael D BartbergerKendall N Houk
Aug 17, 2002·Bioorganic & Medicinal Chemistry Letters·Charles Q MengMartin A Wasserman
Mar 11, 2003·The Journal of Pharmacology and Experimental Therapeutics·Cynthia L SundellUday Saxena
May 24, 2003·Biochemical and Biophysical Research Communications·Yasukazu YoshidaEtsuo Niki
Jul 24, 2003·Journal of the American College of Cardiology·Stavroula K OsganianWalter C Willett
Aug 18, 2004·The International Journal of Biochemistry & Cell Biology·Juan Du, Janusz M Gebicki
Jul 8, 2005·The New England Journal of Medicine·Sotirios TsimikasPeter B Berger
Aug 10, 2005·The Biochemical Journal·Thomas NauserJanusz M Gebicki
Sep 6, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Sundaramahalingam Manikandan, Rathinasamy Sheela Devi
Jan 5, 2007·Journal of Medicinal Food·Shylesh BhaskaranSampath Parthasarathy
Jan 12, 2007·Atherosclerosis·Jean-Claude TardifUNKNOWN CART-2 Investigators
Jul 31, 2007·Molecular and Cellular Biochemistry·Achuthan RadhikaPerumana R Sudhakaran
May 27, 2008·Lancet·Jean-Claude TardifUNKNOWN Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators

❮ Previous
Next ❯

Citations

Jan 31, 2020·Frontiers in Bioengineering and Biotechnology·Alexander VaisermanOleh Lushchak
Dec 31, 2019·Journal of Immunology Research·Hailin XuZhigang Chen
Nov 12, 2020·The International Journal of Biochemistry & Cell Biology·Laszlo A Groh, Niels P Riksen
Jan 30, 2021·Frontiers in Pharmacology·Anastasia V PoznyakAlexander N Orekhov
May 25, 2021·Frontiers in Molecular Biosciences·Olga A ZhuninaAlexander N Orekhov
May 25, 2021·Frontiers in Molecular Biosciences·Ping LinShou-Dong Guo
Jul 20, 2020·Current Drug Metabolism·Pengmian Feng, Lijing Feng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Arteriosclerosis, Thrombosis, and Vascular Biology
N R MadamanchiM S Runge
Antioxidants & Redox Signaling
Raymond ChristonAndre Marette
Pathophysiology : the Official Journal of the International Society for Pathophysiology
Uma Singh, Ishwarlal Jialal
Asian Pacific Journal of Cancer Prevention : APJCP
Ali Reza NourazarianArash Salmaninejad
© 2022 Meta ULC. All rights reserved